Lodoxamide – 250 mg

Brand:
Cayman
CAS:
53882-12-5
Storage:
-20
UN-No:
Non-Hazardous - /

Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.  

 

Available on backorder

SKU: 23994 - 250 mg Category:

Description

A potent agonist of GPR35 (EC50 = 1.61 nM); inhibits histamine release in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM); inhibits A23187-induced calcium influx in isolated rat mast cells; reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml; dose-dependently reduces the immediate hypersensitivity response in rat conjunctiva in vivo; reduces mast cell degranulation in rat conjunctiva


Formal name: 2,2′-[(2-chloro-5-cyano-1,3-phenylene)diimino]bis[2-oxo-acetic acid]

Synonyms: 

Molecular weight: 311.6

CAS: 53882-12-5

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Innate Immunity